Zacks69d agobullish
CANF Stock Soars 20% on Positive Mid-Stage Pancreatic Cancer DataCan-Fite stock jumps 20% after mid-stage data show namodenoson is well tolerated in advanced pancreatic cancer patients, meeting the study's primary safety endpoint.